Symbiotec Pharmalab Ltd

Symbiotec Pharmalab Limited has filed a revised disclosure regarding the encumbrance of shares by promoter Anil Satwani, as per SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The revision clarifies the entity in whose favor the shares are encumbered, specifying Nomura Capital (India) Private Limited as the Lender and Beacon Trusteeship Limited as the Trustee. This update pertains to the re-creation of a pledge for debentures issued under a Debenture Trust Deed, involving 4,50,896 shares (0.70% of total share capital). The original disclosure was filed on September 12, 2026, with the revised filing dated October 16, 2026.

Knovea Pharmaceutical, a wholly owned subsidiary of Symbiotec Pharmalab, has entered into a strategic commercialization agreement with a leading global pharmaceutical company for its Dual Chamber Vial (DCV) based injectable products in the United States. Under the agreement, Knovea will handle development, regulatory submissions, manufacturing, and supply, while the partner will manage commercialization and distribution across the U.S. The collaboration includes milestone payments and profit-sharing. The DCV technology keeps drug and diluent separate until point of care, enhancing stability for sensitive formulations. The two products target a U.S. market estimated at approximately US$288 million. This deal is a significant step for Knovea's DCV platform and Symbiotec's complex injectables business.

Symbiotec Pharmalab Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in effect for all designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter and half-year ended September 30, 2026. The company is adhering to SEBI (Prohibition of Insider Trading) Regulations, 2015, and its internal code of conduct. The specific date for the Board of Directors meeting to approve these results will be communicated later. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Symbiotec Pharmalab Limited has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its manufacturing facility located in Pithampur, Madhya Pradesh, India. The facility was classified with a Voluntary Action Indicated (VAI) status following the inspection, which took place from August 10 to August 14, 2026. This VAI classification indicates that while some issues may have been noted, they do not currently warrant significant regulatory action, suggesting the facility meets acceptable standards for U.S. FDA compliance. This development is positive for the company's export capabilities and market access to the United States.

Symbiotec Pharmalab Limited announced its financial results for Q1 FY27, reporting consolidated revenues of ₹218.2 Cr and a consolidated PAT of ₹14.1 Cr. The API business delivered steady performance with 6% year-on-year growth, achieving operating revenue of ₹215.3 Cr and EBITDA of ₹65.8 Cr. Consolidated EBITDA was ₹45.2 Cr, impacted by ₹35 Cr in expenses from new businesses yet to generate revenue. Operationally, the company successfully completed EUGMP and USFDA audits, filed its first ANDA for Complex Injectables, and secured significant take-or-pay agreements for Biotech - CDMO services. Total gross capex is estimated at ₹1,666 Cr by FY27, with ₹1,000 Cr allocated to new revenue-generating businesses. Net Debt reduced to ₹326 Cr post IPO proceeds, reflecting management's focus on future growth engines.

Symbiotec Pharmalab Ltd's Board of Directors met on September 21, 2026, and approved the unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The company has enclosed the unaudited financial results along with the Limited Review Reports. The trading window for dealing in the company's securities will remain closed until 48 hours after this announcement. The filing also includes the Independent Auditor's Review Report on the quarterly unaudited consolidated financial results.

Symbiotec Pharmalab Ltd's Board of Directors met on September 21, 2026, and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 (Q1 FY27). The company has enclosed the financial results along with the Limited Review Reports. The trading window for dealing in the company's securities will remain closed until 48 hours after this announcement. The results will also be published in newspapers as per SEBI regulations.

Symbiotec Pharmalab Limited's promoter group has re-created a pledge on 4,50,896 equity shares (0.70% of total share capital) in favor of Beacon Trusteeship Limited. This action follows the release of an earlier pledge to facilitate the creation of a lock-in period on pre-issue shareholding as per SEBI ICDR Regulations, 2018, post the company's Initial Public Offer. The company states this is an administrative process with no effective change in the pledged holding. The re-creation of the pledge is linked to debentures issued under a Debenture Trust Deed.

Symbiotec Pharmalab Ltd has announced that its Board of Directors will convene on September 21, 2026. The primary agenda item is the consideration and approval of the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report. The trading window for designated persons and their immediate relatives will remain closed until 48 hours after the declaration of these results. Further details are available on the company's website.

Beacon Trusteeship Limited has filed a disclosure under SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011, regarding the encumbrance of 34,93,464 equity shares of Symbiotec Pharmalab Limited. This encumbrance, representing 5.44% of the total share capital, is in favor of Beacon Trusteeship Limited in its capacity as a debenture trustee. The encumbrance is linked to a debenture trust deed dated December 10, 2025, amended on December 18, 2025, concerning debentures issued by Satwani Holdings (India) Private Limited (SHIPL). The disclosure aligns with information previously provided in Symbiotec Pharmalab's Red Herring Prospectus.